Bayer's investigational stroke drug asundexian met both efficacy and safety goals in the Phase III OCEANIC-STROKE trial. The ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

Stroke Prevention 2.0 focuses on early detection of hidden risks like atrial fibrillation, inflammation, and structural heart defects.

Women who follow the Mediterranean diet have a lower risk of stroke, especially ischemic and hemorrhagic types, according to ...

Rising stroke rates in young adults highlight urgent prevention—manage blood pressure and cholesterol early, address obesity ...

More than 795,000 people in the U.S. have a stroke each year, which is a leading cause of serious long-term disability. Many of the leading risk factors for stroke are modifiable, making prevention ...

A large-scale study finds that women who stick to a Mediterranean eating pattern have a lower risk of stroke, highlighting diet as a key factor in brain health.

Stroke during pregnancy or shortly after delivery is rare, yet it can be life-threatening. Increased awareness and ...